Safety and effectiveness of dofetilide for conversion of atrial fibrillation and nesiritide for acute decompensation of heart failure - A report from the Cardiovascular and Renal Advisory Panel of the Food and Drug Administration

被引:12
作者
Grines, CL [1 ]
机构
[1] William Beaumont Hosp, Div Cardiol, Royal Oak, MI 48073 USA
关键词
anti-arrhythmia agents; atrial flutter; atrial natriuretic factor; heart failure;
D O I
10.1161/01.CIR.101.21.e200
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:E200 / E201
页数:2
相关论文
共 3 条
[1]   Dofetilide - A review of its use in atrial fibrillation and atrial flutter [J].
McClellan, KJ ;
Markham, A .
DRUGS, 1999, 58 (06) :1043-1059
[2]   Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure - A randomized, double-blind, placebo-controlled clinical trial [J].
Mills, RM ;
LeJemtel, TH ;
Horton, DP ;
Liang, CS ;
Lang, R ;
Silver, MA ;
Lui, C ;
Chatterjee, K .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 34 (01) :155-162
[3]   Dofetilide in patients with congestive heart failure and left ventricular dysfunction [J].
Torp-Pedersen, C ;
Moller, M ;
Bloch-Thomsen, PE ;
Kober, L ;
Sandoe, E ;
Egstrup, K ;
Agner, E ;
Carlsen, J ;
Videbæk, J ;
Marchant, B ;
Camm, AJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (12) :857-865